1. Home
  2. DNMX vs FULC Comparison

DNMX vs FULC Comparison

Compare DNMX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynamix Corporation III Class A Ordinary Shares

DNMX

Dynamix Corporation III Class A Ordinary Shares

N/A

Current Price

$10.12

Market Cap

270.2M

Sector

Finance

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.69

Market Cap

281.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DNMX
FULC
Founded
2025
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
270.2M
281.1M
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
DNMX
FULC
Price
$10.12
$3.69
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
★ $3.67
AVG Volume (30 Days)
13.9K
★ 1.2M
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.87
$2.83
52 Week High
$10.15
$15.74

Technical Indicators

Market Signals
Indicator
DNMX
FULC
Relative Strength Index (RSI) 70.67 45.53
Support Level $9.90 $3.62
Resistance Level N/A $3.81
Average True Range (ATR) 0.01 0.06
MACD 0.00 -0.00
Stochastic Oscillator 100.00 7.69

Price Performance

Historical Comparison
DNMX
FULC

About DNMX Dynamix Corporation III Class A Ordinary Shares

Dynamix Corp III is a blank check company.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: